Thrombus Imaging in Acute Stroke: Are We Even Close? Thrombus Imaging in Acute Stroke: Are We Even Close?

Can imaging characteristics of thrombi provide predictive value or useful information for planning endovascular procedures?Stroke
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Related Links:

Sky Medical Technology Ltd. won FDA clearance for a device that stimulates calf muscles to prevent venous thrombosis in non-surgical patients at risk for venous thromboembolism. The Daresbury, England-based company said the geko device is the first muscle pump activator of its kind to be cleared by FDA for VTE prevention across all patients. Sky Medical Technology’s geko is a non-invasive battery-powered, wearable therapy device that is about the size of wristwatch. The technology is worn at the knee. Geko works by gently stimulating the common peroneal nerve, activating the calf and foot muscle pumps, re...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Sky Medical Technology furthers presence in 3.5bn1 dollar US market for VTE prevention DARESBURY, England, Oct. 10, 2019 -- (Healthcare Sales &Marketing Network) -- UK-based medical devices company, Sky Medical Technology Ltd, has received U.S. Food a... Devices, FDA Sky Medical Technology, geko, Deep Vein Thrombosis, venous thromboembolism
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Administration of tissue plasminogen activator (tPA) beyond 4.5 h increases the risk of cerebral hemorrhage. Here, tPA administration during reperfusion at 4.5 or 6  h after middle cerebral artery occlusion or photochemically induced thrombosis in mice caused brain damage with hemorrhage. Co‐administration of prothymosin α (ProTα) or its mimetic hexapeptide (P6Q) inhibited tPA‐induced such brain damage. Therefore, ProTα or P6Q co‐administration would be beneficial to inhibit tPA‐induced hemorrhagic mechanisms in ischemic stroke. AbstractTissue plasminogen activator (tPA) administration beyond...
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Original Article Source Type: research
We report a single-center, retrospective assessment of the safety and efficacy of alteplase treatment within 45 minutes. Methods: Five hundred and eighty-six patients were treated with alteplase in our emergency departments (EDs) between January 2014 and October 2016; 368 patients were included for analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research
ConclusionsIn our study, DOACs appeared to be as efficacious and safe in CKD IV and V as in CKD III. In addition, DOACs appeared to be more effective than, and as safe as warfarin when compared with reference studies of patients with advanced CKD. Our findings support the use of DOACs for thromboembolism prevention in patients with advanced CKD and AF.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - Category: Cardiology Authors: Tags: ELECTROPHYSIOLOGY Source Type: research
Venous thromboembolism, com prising deep vein thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death after stroke and myocardial infarction.1 Anticoagulation is the keystone in venous thromboembolism treatment and prevention of venous thromboembolism morbidity, mortality, and recurrence. International guidelines mandate anticoagulant therapy for a minimum of 3 months after proximal deep vein thrombosis and/or pulmonary embolism.2,3
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Research Study Source Type: research
AbstractBackgroundLeft atrial appendage closure (LAAC) with LARIAT has emerged as one of the alternatives to oral anticoagulation (OAC) in patients with non ‐valvular atrial fibrillation (AF). Our aim was to study long‐term outcomes in patients undergoing LARIAT procedure.MethodsWe analyzed patients screened for LARIAT device in 4 centers between December 2009 and June 2012. Out of these, patients who didn't undergo LAAC with the LARIAT device due to unfavorable LAA morphology and other pre ‐procedural contraindications were included in control group. We analyzed thromboembolism, bleeding events and mortality between...
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: ORIGINAL ‐ CLINICAL Source Type: research
This study evaluated 90 day persistence among patients prescribed rivaroxaban or warfarin for the treatment of acute VTE at an academic safety net hospital. We conducted a single center, retrospective cohort study of 314 consecutive patients newly prescribed rivaroxaban or warfarin for acute VTE between January 2016 and July 2017. Primary outcome was 90 day persistence, and secondary outcomes included 90 day readmission and/or ED visit, time to 90 m day readmission and/or ED visits, and attendance of direct oral anticoagulant education class. Of 314 patients, 78 were prescribed warfarin and 236 rivaroxaban. Patients had a ...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Conclusions: RhPro-UK had an obvious therapeutic effect on ischemic stroke caused by thrombosis, and could be started within 4.5 h TTW with less side effects of cerebral hemorrhage than that of UK. PMID: 31584350 [PubMed - as supplied by publisher]
Source: Neurological Research - Category: Neurology Tags: Neurol Res Source Type: research
ConclusionsOur method supported or altered clinical decision-making and treatment in this cohort. A diagnostic tool for PE without intravenous contrast agent or radiation is of great benefit for certain patients.
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
More News: Brain | Health | Neurology | Neurosurgery | Stroke | Thrombosis